Onconova Therapeutics Inc. Announces Presentation of Favorable Safety and Activity Data From Phase 2 Study of Oral Rigosertib in Lower Risk Myelodysplastic Syndromes
6/3/2013 11:04:47 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEWTOWN, Pa.--(BUSINESS WIRE)--Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of safety and clinical activity data at the American Society of Clinical Oncology Annual Meeting demonstrating an encouraging clinical profile for rigosertib in patients with myelodysplastic syndromes (MDS). The data reported today are interim data from the Phase 2 ONTARGET study which is designed to evaluate oral rigosertib as a single agent in transfusion-dependent lower risk MDS patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by